Lipid Profile Improvements: Omega-3 Fatty Acids vs. Aripiprazole as Adjuncts to Olanzapine Therapy

Dr. Farasat Ali:; Dr. Javaria Fatima: Ali; Dr. Muniza Qayyum:; Dr. Nazia Rashid:; Dr. Aina Sajid:; Dr. Uzma Qayyum:

doi:10.63050/jpps.22.04.1035

Dr. Farasat Ali:
Dr. Javaria Fatima: Ali
Dr. Muniza Qayyum:
Dr. Nazia Rashid:
Dr. Aina Sajid:
Dr. Uzma Qayyum:

DOI: https://doi.org/10.63050/jpps.22.04.1035

Keywords: Shizophrenia, Aripiprazole, Omega 3 Fatty acids, Serum triglycerides, Serum LDL, Olanzapine, metabolic derangements

Abstract

Abstract: Schizophrenia is a psychiatric illness. Pharmacological treatment includes typical and atypical antipsychotics (Olanzapine). Olanzapine causes derangements of lipid profile and glucose metabolism. This study was designed to compare the effects of omega 3 fatty acids (FA) and add on aripiprazole on these metabolic derangements.

Subjects and Methods: Sixty shizophrenic patients (both genders), taking olanzapine and having deranged serum triglyceride and LDL cholesterol were recruited (two groups, Group I and Group II with 30 subjects in each group). Group I was administered 1000 mg omega 3 FA/day/oral at bed time for twelve weeks. Group II was administered aripiprazole 5 mg /day/oral at bed time. Body weight was measured at screening and after 12 weeks. Serum triglyceride and serum LDL cholesterol of both groups were measured at screening (0 day), 6 weeks and after 12 weeks. Collected data was analyzed using SPSS 20.

Results: After 12 weeks Group I showed 19% and Group II 15 % reduction in body weight. Group I showed 22 % reduction and Group II depicted 20 % reduction in serum triglyceride. Serum LDL cholesterol of Group I showed 20 % and group II 19 % reduction. Body weight, serum triglyceride and LDL cholesterol of Group I and Group II had significantly (≤0.05) reduced as compared to screening.

Conclusion: Treatment with omega 3 FA and aripiprazole successfully reduced body weight, serum triglycerides and LDL cholesterol.

Downloads

Download data is not yet available.

Author Biographies

Dr. Farasat Ali:

Associate Professor Psychiatry, Unit B. PIMH. Lahore.

MBBS, FCPS Psychiatry

Dr. Javaria Fatima: Ali

Assisitant Professor, Pharmacology department, AAMC, Lahore.

MBBS, M.Phil Pharmacology

Dr. Muniza Qayyum:

Professor, Pharmacology department, FJMU, Lahore.

MBBS, M.Phil, PHD Pharmacology

Dr. Nazia Rashid:

Associate Professor, Pharmacology department, FJMU, Lahore.

MBBS, M.Phil, Pharmacology

Dr. Aina Sajid:

PGR. Psychiatry, Unit B. PIMH. Lahore.

Dr. Uzma Qayyum:

PGR. Psychiatry, Unit B. PIMH. Lahore.

References

1. Sonnenschein SF, Gomes FV, Grace AA. Dysregulation of midbrain dopamine
system and the pathophysiology of schizophrenia. Frontiers in psychiatry. 2020 Jun
30;11:613.

2. McCutcheon RA, Krystal JH, Howes OD. Dopamine and glutamate in schizophrenia: biology, symptoms and treatment. World Psychiatry. 2020 Feb;19(1):15-33.

3. Nawaz R, Gul S, Amin R, Huma T, Al Mughairbi F. Overview of schizophrenia research and treatment in Pakistan. Heliyon. 2020 Nov 1;6(11):e05545.

4. Kane JM, Correll CU. Pharmacologic treatment of schizophrenia. Dialogues in clinical neuroscience. 2022 Apr 1.

5. Hussain S, Imtiaz N, Amin MA, Khan S, Kakar S. Comparison of two widely used atypical antipsychotics olanzapine versus risperidone in terms of metabolic outcomes. PAFMJ. 2021 Jan 27;71(Suppl-1):S147-52.

6. Xu F, Fan W, Wang W, Tang W, Yang F, Zhang Y, Cai J, Song L, Zhang C. Effects of omega-3 fatty acids on metabolic syndrome in patients with schizophrenia: a 12-week randomized placebo-controlled trial. Psychopharmacology. 2019 Apr;236(4):1273-9.

7. Henderson DC, Fan X, Copeland PM, Sharma B, Borba CP, Boxill R, Freudenreich O, Cather C, Evins AE, Goff DC. Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients. Journal of clinical psychopharmacology. 2009 Apr;29(2):165.

8. Hsu MC, Huang YS, Ouyang WC. Beneficial effects of omega-3 fatty acid supplementation in schizophrenia: possible mechanisms. Lipids in Health and Disease. 2020 Dec;19:1-7.

9. Behdani F, Roudbaraki SN, Saberi-Karimian M, Tayefi M, Hebrani P, Akhavanrezayat A, Amlashi SV, Ferns GA, Ghayour-Mobarhan M. Assessment of the efficacy of omega-3 fatty acids on metabolic and inflammatory parameters in patients with schizophrenia taking clozapine and sodium valproate. Psychiatry Research. 2018 Mar 1;261:243-7.

10. Vancampfort D, Firth J, Correll CU, Solmi M, Siskind D, De Hert M, Carney R, Koyanagi A, Carvalho AF, Gaughran F, Stubbs B. The impact of pharmacological and non‐pharmacological interventions to improve physical health outcomes in people with schizophrenia: a meta‐review of meta‐analyses of randomized controlled trials. World Psychiatry. 2019 Feb;18(1):53-66
11. Lee CH, Fu Y, Yang SJ, Chi CC. Effects of omega-3 polyunsaturated fatty acid supplementation on non-alcoholic fatty liver: a systematic review and meta-analysis. Nutrients. 2020 Sep 11;12(9):2769.
12. Chen L, Selvendra A, Stewart A, Castle D. Risk factors in early and late onset schizophrenia. Comprehensive Psychiatry. 2018 Jan 1;80:155-62.
13. Holdorovna IM, Temirpulatovich TB. Optimization of complex methods of treatment of patients in schizophrenia. Journal of education, ethics and value. 2023 Aug 19;2(8):59-67.
14. Citrome L, McEvoy JP, Todtenkopf MS, McDonnell D, Weiden PJ. A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future. Neuropsychiatric disease and treatment. 2019 Sep 5:2559-69.
15. Khaleel SM, Khalaf MM, Hasan MS. Potential Mitigation of Olanzapine-induced Derangement of Blood Sugars by Adding Aripiprazole to the Therapeutic Regimen of patients with Schizophrenia: A Follow-up Study. Systematic Reviews in Pharmacy. 2020 Aug 1;11(8).
16. Jankajova M, Pella D, Zenuch P, Zenuchova Z, Toth S, Kalanin P, Fedacko J. The Role of W3 PUFFA in Patients with Metabolic Syndrome and Endothelial Dysfunction.
17. Samyukta K, Shivson D, KantiPuDi SJ. Effect of Olanzapine on metabolic syndrome-a one year follow-up study. J Clin Diagnostic Res. 2020 Jun 1;14(6).
18. Komal F, Khan MK, Imran M, Ahmad MH, Anwar H, Ashfaq UA, Ahmad N, Masroor A, Ahmad RS, Nadeem M, Nisa MU. Impact of different omega-3 fatty acid sources on lipid, hormonal, blood glucose, weight gain and histopathological damages profile in PCOS rat model. Journal of Translational Medicine. 2020 Dec;18:1-1.
19. Bays HE, Tighe AP, Sadovsky R, Davidson MH. Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications. Expert review of cardiovascular therapy. 2008 Mar 1;6(3):391-409.
20. Skrede S, Fernø J, Vázquez MJ, Fjær S, Pavlin T, Lunder N, Vidal-Puig A, Diéguez C, Berge RK, López M, Steen VM. Olanzapine, but not aripiprazole, weight-independently elevates serum triglycerides and activates lipogenic gene expression in female rats. International Journal of Neuropsychopharmacology. 2012 Mar 1;15(2):163-79.
21. Kirschbaum KM, Müller MJ, Malevani J, Mobascher A, Burchardt C, Piel M, Hiemke C. Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side effects. The World Journal of Biological Psychiatry. 2008 Jan 1;9(3):212-8.